Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Latin American Examiner.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on April 30, 2025
Emerita Files NI 43-101 Technical Report for the IBW Project, Marking a 35% Increase in Total Indicated Resources and a 44% Increase in Total Inferred Resources
GlobeNewswire
·
April 30, 2025
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX – V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) reports that it has filed the independent NI 43-101 compliant technical report for its Iberian Belt West Project (“IBW” …
XORTX Provides Update on FDA Type B Meeting Request
GlobeNewswire
·
April 30, 2025
● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical …
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
GlobeNewswire
·
April 30, 2025
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 …
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
GlobeNewswire
·
April 30, 2025
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial. OKYO Pharma plans to analyze the efficacy data from the 17 patients who …
Banco Itaú Chile Announces First Quarter 2025 Management Discussion & Analysis Report
GlobeNewswire
·
April 30, 2025
SANTIAGO, Chile, April 30, 2025 (GLOBE NEWSWIRE) -- BANCO ITAÚ CHILE (SSE: ITAUCL) announced today its Management Discussion …
PL BioScience Launches World’s Only Patented Gamma-irradiated Human Platelet Lysate
GlobeNewswire
·
April 30, 2025
New high-quality cell growth supplement for cell manufacturing applications including in regenerative medicine and cell therapies Human Platelet Lysate (HPL) offers a safer and sustainable alternative to Fetal Bovine/ Calf Serum (FBS/FCS) Gamma-irradiated …
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
GlobeNewswire
·
April 30, 2025
ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma …
Fortuna renews share repurchase program
GlobeNewswire
·
April 30, 2025
VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) announced today that the Toronto Stock Exchange has approved the renewal of Fortuna’s normal course issuer bid (the “NCIB”) to purchase up to five …
Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel
GlobeNewswire
·
April 30, 2025
VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to …
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
GlobeNewswire
·
April 30, 2025
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. …